| Literature DB >> 33148311 |
Nicolas Delvaux1, Veerle Piessens2, Tine De Burghgraeve3, Pavlos Mamouris3, Bert Vaes3, Robert Vander Stichele4, Hanne Cloetens5, Josse Thomas6, Dirk Ramaekers3, An De Sutter2, Bert Aertgeerts3.
Abstract
BACKGROUND: Inappropriate laboratory test ordering poses an important burden for healthcare. Clinical decision support systems (CDSS) have been cited as promising tools to improve laboratory test ordering behavior. The objectives of this study were to evaluate the effects of an intervention that integrated a clinical decision support service into a computerized physician order entry (CPOE) on the appropriateness and volume of laboratory test ordering, and on diagnostic error in primary care.Entities:
Mesh:
Year: 2020 PMID: 33148311 PMCID: PMC7640389 DOI: 10.1186/s13012-020-01059-y
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Fig. 1Flow of patient recruitment. CDSS, clinical decision support system; ID, identifier
Demographics of patients. Characteristics of GPs participating in the study and included patients
| CDSS arm | Control arm | Total | |
|---|---|---|---|
| Number of GPs | 135 (49.63%) | 137 (50.37%) | 272 |
| Age (mean years, SD) | 41 (13.59) | 41 (13.27) | |
| Experience (mean years, SD) | 14 (18.81) | 15 (19.40) | |
| % Female | 65.00 | 62.14 | |
| Number of practices per lab | 36 (50.00%) | 36 (50.00%) | 72 |
| Laboratory 1 | 19 (52.78%) | 20 (55.56%) | 39 |
| Laboratory 2 | 5 (13.89%) | 3 (8.33%) | 8 |
| Laboratory 3 | 12 (33.33%) | 13 (36.31%) | 25 |
| Number patients | 5124 (52.92%) | 4559 (47.08%) | 9683 |
| Age (years, SD) | 58.33 (17.04) | 54.34 (17.61) | 56.45 (17.42) |
| Female sex ( | 2774 (54.00%) | 2578 (56.00%) | 5352 (55.10%) |
| Total number of panels ( | 5495 (53.51%) | 4775 (46.49%) | 10,270 |
| Number of panels per indication ( | |||
| Check-up | 1722 (31.34%) | 1936 (40.54%) | 3658 (35.62%) |
| Cardiovascular disease management | 1381 (25.13%) | 585 (12.25%) | 1966 (19.14%) |
| Hypertension | 889 (16.18%) | 478 (10.01%) | 1367 (13.31%) |
| Chronic kidney disease | 587 (10.68%) | 168 (3.52%) | 755 (7.35%) |
| Type 2 diabetes | 2160 (39.31%) | 953 (19.96%) | 3113 (30.31%) |
| Thyroid disease | 1164 (21.18%) | 576 (12.06%) | 1740 (16.94%) |
| Sexually transmitted infections | 248 (4.51%) | 336 (7.04%) | 584 (5.69%) |
| Chronic diarrhea | 23 (0.42%) | 42 (0.88%) | 65 (0.63%) |
| Acute diarrhea | 12 (0.22%) | 19 (0.40%) | 31 (0.30%) |
| Acute coronary syndrome | 34 (0.62%) | 21 (0.44%) | 55 (0.54%) |
| Lung embolism | 22 (0.40%) | 15 (0.31%) | 37 (0.36%) |
| Rheumatoid arthritis | 126 (2.29%) | 105 (2.20%) | 231 (2.25%) |
| Medication follow-up | 798 (14.52%) | 374 (7.83%) | 1172 (11.41%) |
| Gout | 170 (3.09%) | 39 (0.82%) | 209 (2.04%) |
| Liver disease | 416 (7.57%) | 157 (3.29%) | 573 (5.58%) |
| Anemia | 728 (13.25%) | 395 (8.27%) | 1123 (10.93%) |
| Fatigue | 606 (11.03%) | 520 (10.89%) | 1126 (10.96%) |
| Other | 434 (7.90%) | 621 (13.01%) | 1055 (10.27%) |
GP general practitioner, CDSS clinical decision support system, SD standard deviation
aThe percentages reported for the individual indications use the total number of panels as denominator
Effect of CDSS on proportion of appropriate tests. All values are absolute differences with 95% confidence intervals unless specified otherwise
| Proportion appropriate tests | Difference in proportions | |||
|---|---|---|---|---|
| CDSS arm | Control arm | |||
| Primary outcome (all tests) | 0.58 (0.54–0.62) | 0.38 (0.34–0.41) | 0.21 (0.16–0.26) | < 0.0001 |
| Subgroups per indication | ||||
| Check-up | 0.26 (0.24–0.28) | 0.17 (0.16–0.19) | 0.08 (0.06–0.11) | < 0.0001 |
| Medication follow-up | 0.78 (0.75–0.82) | 0.74 (0.70–0.78) | 0.04 (0.00–0.09) | 0.0591 |
| Cardiovascular disease management | 0.41 (0.37–0.45) | 0.30 (0.28–0.32) | 0.11 (0.07–0.15) | < 0.0001 |
| Hypertension | 0.47 (0.43–0.50) | 0.39 (0.35–0.42) | 0.08 (0.03–0.12) | 0.0007 |
| Type 2 diabetes | 0.51 (0.47–0.54) | 0.38 (0.35–0.41) | 0.13 (0.08–0.17) | < 0.0001 |
| Fatigue | 0.81 (0.79–0.83) | 0.67 (0.64–0.70) | 0.14 (0.10–0.17) | < 0.0001 |
| Anemia | 0.82 (0.81–0.84) | 0.76 (0.74–0.78) | 0.06 (0.03–0.09) | < 0.0001 |
| Liver disease | 0.56 (0.53–0.59) | 0.43 (0.39–0.46) | 0.13 (0.08–0.18) | < 0.0001 |
| Gout | 0.27 (0.23–0.31) | 0.16 (0.14–0.18) | 0.11 (0.06–0.16) | < 0.0001 |
| Chronic kidney disease | 0.66 (0.61–0.70) | 0.51 (0.46–0.56) | 0.14 (0.09–0.20) | < 0.0001 |
| Acute coronary syndrome | 0.06 (0.05–0.07) | 0.04 (0.02–0.05) | 0.02 (0.01–0.04) | 0.0081 |
| Lung embolisma | 0.06 (0.02–0.10) | 0.02 (0.01–0.04) | 0.03 (− 0.01–0.08) | 0.1608 |
| Rheumatoid arthritis | 0.79 (0.76–0.82) | 0.61 (0.56–0.66) | 0.18 (0.12–0.24) | < 0.0001 |
| Thyroid disease | 0.50 (0.47–0.54) | 0.45 (0.42–0.49) | 0.05 (0.01–0.09) | 0.0136 |
| Sexually transmitted infections | 0.29 (0.23–0.36) | 0.33 (0.27–0.39) | − 0.04 (− 0.13–0.06) | 0.4719 |
| Acute diarrhea | 0.54 (0.46–0.62) | 0.33 (0.28–0.38) | 0.22 (0.10–0.33) | 0.0002 |
| Chronic diarrhea | 0.41 (0.34–0.49) | 0.25 (0.22–0.29) | 0.16 (0.08–0.24) | 0.0001 |
CDSS clinical decision support system
aNumbers do not include corrections for the laboratory and the number of study indications per panel